JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL

Preventing or overcoming resistance to the Bcl‐2 inhibitor venetoclax is an emerging unmet clinical need in patients with chronic lymphocytic leukaemia (CLL). The upregulation of anti‐apoptotic Bcl‐2 members through signalling pathways within the tumor microenvironment appears as a major factor lead...

Full description

Bibliographic Details
Main Authors: Marco V. Haselager, Rachel Thijssen, Danique Bax, Demi Both, Francien De Boer, Simon Mackay, Julie Dubois, Clemens Mellink, Arnon P. Kater, Eric Eldering
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Molecular Oncology
Subjects:
chronic lymphocytic leukaemia
drug resistance
microenvironment
signalling
Online Access:https://doi.org/10.1002/1878-0261.13364

Similar Items

Similar Items